Obefazimod

Obefazimod
Identifiers
	IUPAC name 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine;
CAS Number	1258453-75-6;
PubChem CID	49846599;
DrugBank	DB14828;
ChemSpider	34537418;
UNII	26RU378B9V;
KEGG	D12345;
ChEMBL	ChEMBL4297344;
Chemical and physical data
Formula	C16H10ClF3N2O
Molar mass	338.71 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F;
	InChI InChI=1S/C16H10ClF3N2O/c17-13-3-1-2-10-4-9-14(22-15(10)13)21-11-5-7-12(8-6-11)23-16(18,19)20/h1-9H,(H,21,22); Key:OZOGDCZJYVSUBR-UHFFFAOYSA-N;

Obefazimod is an investigational new drug that is being evaluated for the treatment of ulcerative colitis.^[1] It is miR-124 micro RNA upregulator.^[2] Obefazimod was developed by the French biotech company Abivax SA, whose shares rose by more than 500% when the phase 3 data showed promising results.

References

^ "Obefazimod - Abivax". AdisInsight. Springer Nature Switzerland AG.
^ Datta N, Johnson C, Kao D, Gurnani P, Alexander C, Polytarchou C, et al. (August 2023). "MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis". Pharmacological Research. 194 106870. doi:10.1016/j.phrs.2023.106870. PMID 37499702.

[1] "Obefazimod - Abivax". AdisInsight. Springer Nature Switzerland AG.

[Datta_2023-2] Datta N, Johnson C, Kao D, Gurnani P, Alexander C, Polytarchou C, et al. (August 2023). "MicroRNA-based therapeutics for inflammatory disorders of the microbiota-gut-brain axis". Pharmacological Research. 194 106870. doi:10.1016/j.phrs.2023.106870. PMID 37499702.

[1]

[2]